Drug intelligence / Profile preview

CelaEase

Development stage: Preclinical
Lead developer: Harding University
Modality: Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

CelaEase is a topical dermal gel product in development by CelaCare Technologies for **herpes zoster**. The product is described as an antiviral and antimicrobial topical formulation directed at **varicella-zoster virus**, using a silver citrate complex for local antimicrobial activity and acemannan to support tissue repair.

Brand names: CelaEase Dermal GelCelaEase
Other names: CelaEaseCelaEase Dermal Gel

Beyond the preview

Go deeper on CelaEase.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CelaEase.

Explore the full profile